Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1343
mi
from
New Haven, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Norman S. Werdiger, MD
1343
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1344
mi
from
New Haven, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Institutional Review Board / Ethics Committee
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1343
mi
from
New Haven, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Yale PET Center
1343
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1318
mi
from
Norwalk, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Research Center for Clinical Studies, Inc.
1318
mi
from
Norwalk, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1338
mi
from
Waterbury, CT
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Chase Medical Research, LLC
1338
mi
from
Waterbury, CT
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1287
mi
from
Atlantis, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
JEM Research Institute
1287
mi
from
Atlantis, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1287
mi
from
Atlantis, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Medical Specialists of the Palm Beaches
1287
mi
from
Atlantis, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1132
mi
from
Bradenton, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Bradenton Research Center, Incorporated
1132
mi
from
Bradenton, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1301
mi
from
Deerfield Beach, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
North Broward Medical Center
1301
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1293
mi
from
Delray Beach, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Brain Matters Research
1293
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1305
mi
from
Fort Lauderdale, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Neurologic Consultants, PA
1305
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1313
mi
from
Hallandale Beach, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
MD Clinical
1313
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1078
mi
from
Ocala, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Renstar Medical Research
1078
mi
from
Ocala, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1073
mi
from
Ocala, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Advanced Imaging
1073
mi
from
Ocala, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1141
mi
from
Orlando, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Compass Research LLC
1141
mi
from
Orlando, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1276
mi
from
Palm Beach Gardens, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Palm Beach Neurological Center,
1276
mi
from
Palm Beach Gardens, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1177
mi
from
Port Charlotte, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Neurostudies, Inc.
1177
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1138
mi
from
Sarasota, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Roskamp Institute
1138
mi
from
Sarasota, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1132
mi
from
Sun City, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
South Bay Internal Medicine
1132
mi
from
Sun City, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1112
mi
from
Tampa, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Stedman Clinical Trials
1112
mi
from
Tampa, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1281
mi
from
West Palm Beach, FL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Premiere Research Institute
1281
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
798
mi
from
Atlanta, GA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
NeuroTrials Research, Incorporated
798
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
811
mi
from
Columbus, GA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Columbus Diagnostic Center (MRI)
811
mi
from
Columbus, GA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
811
mi
from
Columbus, GA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Medical Research and Health Education Foundation, Incorporated
811
mi
from
Columbus, GA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
805
mi
from
Decatur, GA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC
805
mi
from
Decatur, GA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
805
mi
from
Decatur, GA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
NeuroStudies.net
805
mi
from
Decatur, GA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
821
mi
from
Lawerenceville, GA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Neurostudies.net
821
mi
from
Lawerenceville, GA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
816
mi
from
Lawrenceville, GA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Neurostudies.net
816
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
598
mi
from
Elk Grove Village, IL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Alexian Brothers Medical Center
598
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
597
mi
from
Elk Grove Village, IL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Alexian Brothers Neurosciences Institute
597
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
483
mi
from
Peoria, IL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Methodist Center for Senior Health
483
mi
from
Peoria, IL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
483
mi
from
Peoria, IL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Methodist Medical Center Research Department
483
mi
from
Peoria, IL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
483
mi
from
Peoria, IL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Methodist Diagnostic Center
483
mi
from
Peoria, IL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
484
mi
from
Peoria, IL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Methodist Medical Center of Illinois
484
mi
from
Peoria, IL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
462
mi
from
Springfield, IL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Southern Illinois University School of Medicine
462
mi
from
Springfield, IL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
462
mi
from
Springfield, IL
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Memorial Medical Center
462
mi
from
Springfield, IL
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
685
mi
from
Elkhart, IN
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Elkhart Clinic, LLC
685
mi
from
Elkhart, IN
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
675
mi
from
Mishawaka, IN
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Psychology Associates
675
mi
from
Mishawaka, IN
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
26
mi
from
Wichita, KA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
KU - Wichita
26
mi
from
Wichita, KA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
22
mi
from
Wichitia, KA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Drug Shipment/ Storage
22
mi
from
Wichitia, KA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
mi
from
Paducah, KY
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Four Rivers Clinical Research, Incorporated
mi
from
Paducah, KY
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
507
mi
from
Paducah, KY
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Radio Pharmacy
507
mi
from
Paducah, KY
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
583
mi
from
Lake Charles, LA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Lake Charles Clinical Trials LLC
583
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
700
mi
from
New Orleans, LA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Louisiana Research Associates, Inc.
700
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
428
mi
from
Shreveport, LA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
James Gary Booker, MD, APMC
428
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1123
mi
from
Bethesda, MD
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Foers Medical Arts Pharmacy
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1120
mi
from
Rockville, MD
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
CBH Health LLC
1120
mi
from
Rockville, MD
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1443
mi
from
Boston, MA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1444
mi
from
Boston, MA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Brigham and Women's Hosp
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated:  12/4/2015
1444
mi
from
Boston, MA
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
Status: Enrolling
Updated: 12/4/2015
Bringham and Women's Hospital
1444
mi
from
Boston, MA
Click here to add this to my saved trials